Trial Profile
A randomized, open-label study of PEGASYS compared with daily vitamin E on fibrosis progression in patients with chronic viral infection nonresponsive to pegylated interferon plus ribavirin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2011
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Tocopherol (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms FIBROSYS
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 23 Feb 2010 Planned number of patients changed from 100 to 106 as reported by Roche record.
- 08 Jun 2006 New trial record.